Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
1 . A method of treating depression comprising the steps of:
a) identifying a subject with a depressive disorder or identifying a subject with one or more symptoms of a depressive disorder; and
b) administering an effective amount of a composition comprising a botulinum toxin and a pharmaceutically acceptable carrier to said subject thereby reducing at least one symptom of depression.
2 . The method of claim 1 , wherein the botulinum toxin is immunotype A, B, C, D, E, F, or G.
3 . The method of claim 1 , wherein the botulinum toxin is botulinum toxin type A from Hall strain Clostridium botulinum.
4 . The method of claim 1 , wherein the composition is administered by injection.
5 . The method of claim 1 , wherein there are at least two injection sites.
6 . The method of claim 4 , wherein the injection is multifocal.
7 . The method of claim 4 , wherein the composition is administered to the forehead.
8 . The method of claim 4 , wherein the composition is administered to the scalp.
9 . The method of claim 4 , wherein the composition is administered to the neck.
10 . A method of treating a depressive disorder comprising the steps of:
a) identifying a subject with a depressive disorder or identifying a subject with one or more symptoms of a depressive disorder;
b) administering to said subject a composition comprising a neurotoxin and a pharmaceutically acceptable carrier wherein said composition is delivered across a blood brain barrier in an amount sufficient to decrease cholinergic neuron transmission.
11 . The method of claim 10 , wherein said composition decreases choline acetyltransferase activity.
12 . The method of claim 10 , wherein said composition decreases synthesis of acetylcholine.
13 . The method of claim 10 , wherein said neurotoxin is a Clostridium botulinum neurotoxin.
14 . The method of claim 13 wherein said botulinum neurotoxin is immunotype A, B, C, D, E, F, or G.
15 . The method of claim 14 , wherein said Clostridium botulinum is Hall strain.
16 . The method of claim 10 , wherein administration is by injection.
17 . The method of claim 16 , wherein the injection is multifocal.
18 . The method of claim 16 , wherein the composition is administered to the brow or forehead.
19 . The method of claim 16 , wherein the composition is administered to the scalp.
20 . The method of claim 16 , wherein the composition is administered to the neck.